| Basics |
|
Relmada Therapeutics, Inc.
|
| IPO Date: |
June 16, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$310.93M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.53 | 3.89%
|
| Avg Daily Range (30 D): |
$0.17 | 5.40%
|
| Avg Daily Range (90 D): |
$0.12 | 6.12%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.34M |
| Avg Daily Volume (30 D): |
1.21M |
| Avg Daily Volume (90 D): |
.82M |
| Trade Size |
| Avg Trade Size (Sh.): |
133 |
| Avg Trade Size (Sh.) (30 D): |
116 |
| Avg Trade Size (Sh.) (90 D): |
164 |
| Institutional Trades |
| Total Inst.Trades: |
368 |
| Avg Inst. Trade: |
$2.17M |
| Avg Inst. Trade (30 D): |
$1.16M |
| Avg Inst. Trade (90 D): |
$1.16M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.27M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
102.03K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.3
|
$-.3
|
$-.58
|
|
Diluted EPS
|
$-.3
|
$-.3
|
$-.58
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -10.09M
|
$ -9.87M
|
$ -17.56M
|
|
Operating Income / Loss
|
$ -10.33M
|
$ -10.22M
|
$ -18.22M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ .03M
|
$ -2.5M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 30, 2019:
1:4
|
|
Aug 12, 2015:
1:5
|
|
|
|